[go: up one dir, main page]

WO2002036748A3 - Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells - Google Patents

Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells Download PDF

Info

Publication number
WO2002036748A3
WO2002036748A3 PCT/US2001/046333 US0146333W WO0236748A3 WO 2002036748 A3 WO2002036748 A3 WO 2002036748A3 US 0146333 W US0146333 W US 0146333W WO 0236748 A3 WO0236748 A3 WO 0236748A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell population
antigen
reactive
alloreactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/046333
Other languages
French (fr)
Other versions
WO2002036748A2 (en
Inventor
Mohammad Luqman
James G Bender
Epps Dennis E Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexell Therapeutics Inc
Original Assignee
Nexell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexell Therapeutics Inc filed Critical Nexell Therapeutics Inc
Priority to AU2002218019A priority Critical patent/AU2002218019A1/en
Publication of WO2002036748A2 publication Critical patent/WO2002036748A2/en
Anticipated expiration legal-status Critical
Publication of WO2002036748A3 publication Critical patent/WO2002036748A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides methods for depleting alloreactive or antigen-reactive T cells from a hematopoietic donor cell population, by co-culturing a recipient-derived dendritic cell population or cultured macrophage population with the donor cell population, under conditions wherein the recipient-derived population activates donor T cells in the donor cell population, and killing or removing the activated T cells. Also provided are hematopoietic donor cell population depleted of, or enriched for, alloreactive or antigen-reactive T cells prepared by these methods. The invention further provides methods of using the depleted and isolated hematopoietic donor cell population in transplant procedures.
PCT/US2001/046333 2000-11-03 2001-10-31 Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells Ceased WO2002036748A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002218019A AU2002218019A1 (en) 2000-11-03 2001-10-31 Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70633700A 2000-11-03 2000-11-03
US09/706,337 2000-11-03

Publications (2)

Publication Number Publication Date
WO2002036748A2 WO2002036748A2 (en) 2002-05-10
WO2002036748A3 true WO2002036748A3 (en) 2003-10-02

Family

ID=24837124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046333 Ceased WO2002036748A2 (en) 2000-11-03 2001-10-31 Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells

Country Status (2)

Country Link
AU (1) AU2002218019A1 (en)
WO (1) WO2002036748A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458406A4 (en) * 2001-10-24 2006-04-19 Order Sisters Of Mercy Queensl A method of treatment and agents useful for same
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
BRPI0411127A (en) * 2003-06-10 2006-05-23 Univ Melbourne composition of matter for immune response modulation in a subject antigen subject and its modulation method, antigen presenting cell production process and method of treatment and / or prophylaxis of disease or condition associated with the presence of target antigen of interest
WO2009036521A1 (en) 2007-09-20 2009-03-26 St Vincent's Hospital Sydney Limited A method for identifying antigen-specific regulatory t cells
WO2016176193A1 (en) * 2015-04-27 2016-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the selective depletion of alloreactive t lymphocytes from donor stem cell or lymphocyte grafts to prevent graft-versus-host disease
CN109666640B (en) * 2019-01-14 2020-06-16 武汉睿健医药科技有限公司 A method for pure culture of natural killer cells in vitro
WO2021163472A1 (en) * 2020-02-14 2021-08-19 The General Hospital Corporation Monitoring viability of organs for transplantation
US20250084370A1 (en) * 2021-07-29 2025-03-13 Transimmune Ag Methods for selectively reducing immunogenicity in a transplant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO1999005173A1 (en) * 1997-07-23 1999-02-04 Rijksuniversiteit Te Leiden The ha-1 antigen
WO1999024078A1 (en) * 1997-11-12 1999-05-20 The Trustees Of The University Of Pennsylvania Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
EP0922758A2 (en) * 1997-10-27 1999-06-16 Rockefeller University Methods and compositions for obtaining mature dendritic cells
WO2000000825A2 (en) * 1998-06-30 2000-01-06 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
WO2001030369A1 (en) * 1999-10-22 2001-05-03 Biotransplant, Inc. Process for inducing immunological tolerance for xenogeneic transplants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003976A2 (en) * 1997-07-21 1999-01-28 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO1999005173A1 (en) * 1997-07-23 1999-02-04 Rijksuniversiteit Te Leiden The ha-1 antigen
EP0922758A2 (en) * 1997-10-27 1999-06-16 Rockefeller University Methods and compositions for obtaining mature dendritic cells
WO1999024078A1 (en) * 1997-11-12 1999-05-20 The Trustees Of The University Of Pennsylvania Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
WO2000000825A2 (en) * 1998-06-30 2000-01-06 The Rockefeller University Detection and modulation of cellular immunity to immune privileged antigens
WO2001030369A1 (en) * 1999-10-22 2001-05-03 Biotransplant, Inc. Process for inducing immunological tolerance for xenogeneic transplants

Also Published As

Publication number Publication date
AU2002218019A1 (en) 2002-05-15
WO2002036748A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
WO2005047524A3 (en) Compositions and methods for inducing cell dedifferentiation
WO2005116073A3 (en) Pdx1 expressing endoderm
WO2006094286A3 (en) Adult pancreatic derived stromal cells
EP2471905A3 (en) Placental stem cell populations
EP2722387A3 (en) Definitive endoderm
WO2004096975A3 (en) Apparatus and methods for amplification of blood stem cell numbers
WO2001011011A3 (en) Multipotent adult stem cells and methods for isolation
WO2004070013A3 (en) Use of islet 1 as a marker for isolating or generating stem cells
WO2004076651A3 (en) Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
WO2000047720A3 (en) Pancreatic progenitor cells, methods and uses related thereto
WO2005079145A3 (en) Tissue system with undifferentiated stem cells derived from corneal limbus
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
EP2410043A3 (en) Stem cells culture systems
WO2003024406A3 (en) Nestin-expressing hair follicle stem cells
WO2000046585A3 (en) Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose
TW200741001A (en) Method for production of t cell population
AU2003903896A0 (en) Skin regeneration system
WO2006071410A3 (en) Apparatus and system having dry gene silencing compositions
WO2002036748A3 (en) Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
WO2006047743A3 (en) Swine multipotent adult progenitor cells
WO2003042113A8 (en) Production of cell suspensions
WO2003010292A3 (en) Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
WO2004066937A3 (en) Antibodies specific for plasmacytoid dendritic cells
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
AU2001278700A1 (en) Method of culturing human chondrocytes

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP